Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it ...

Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in ...

Alphabet Inc.’s Isomorphic Labs raised $2.1 billion in its second round of outside capital, with new support from sovereign wealth funds, as it seeks to make artificial intelligence-designed drugs a ...

If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...

Thrive Capital and Alphabet are leading new financing for Isomorphic Labs, the AI-powered drug discovery company.

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.” Isomorphic Labs, the UK-based biotech spinoff of ...

Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful ...

The unified JavaScript runtime standard is an idea whose time has come. Here’s an inside look at the movement for server-side JavaScript interoperability. The WinterCG community group was recently ...

Nearly two years after Google DeepMind released AlphaFold 3, an updated version of its system for predicting protein structure that is geared towards drug discovery, its biopharmaceuticals spin-off, ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Isomorphic Labs, a subsidiary of Alphabet Inc., is trying to use artificial intelligence to understand biology and transform the way new medicines are discovered and developed. Bloomberg's Tom ...